<DOC>
	<DOCNO>NCT02401295</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability associate combination ATRA/celecoxib/itraconazole maintenance therapy give autologous stem cell transplant relapse multiple myeloma patient .</brief_summary>
	<brief_title>ATRA , Celecoxib , Itraconazole Maintenance</brief_title>
	<detailed_description>Primary objective : To evaluate safety tolerability associate combination ATRA/ celecoxib/itraconazole give salvage transplant relapse myeloma 25 patient cycle schedule consist three week treatment follow rest period two week total five cycle . Subjects evaluable receive least one dose maintenance treatment . The salvage transplant part study . Secondary objective : To explore change frequency molecular signature multiple myeloma stem cell ( MMSC ) fraction base flow-cytometric assay gene expression profile experimental treatment correlate outcome expression level RARα2 time relapse .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Diagnosis relapse multiple myeloma Recent salvage transplant ( ≤ 6 month ≥ 45 day posttransplant prior study enrollment ) relapse 1875 year age time study entry Platelet count ≥70K/mm3 untransfused Resolution transplantrelated toxicity ≤ grade 2 per CTCAE v.4 Left ventricular ejection fraction measure ECHO MUGA ≥ 40 % Creatinine ≤ 2 mg/dl calculate GFR &gt; 50mL/min/1.73m2 A total bilirubin , ALT , AST , alkaline phosphatase ≤ 2 ULN Performance status 02 base ECOG criterion . Patients performance status 3 4 , base solely bone pain , also eligible , provide source document verify Prospective study participant must inform investigational nature study must sign IRBapproved informed consent form accordance institutional federal guideline Prior allogeneic transplant Greater grade 2 motor neuropathy great grade 3 sensory neuropathy screening Uncontrolled diabetes Recent ( &lt; 6 month ) myocardial infarction , unstable angina , CABG stent placement last 2 year , difficulttocontrol congestive heart failure , uncontrolled hypertension ( systolic blood pressure &gt; 160 mm diastolic BP &gt; 110 mm normal condition appropriate antihypertensive medication ) , difficult tocontrol cardiac arrhythmia Evidence QT prolongation and/or torsades de pointes ( TdP ) EKG . Any comorbid condition pose great threat patient 's life expectancy recurrent myeloma No concurrent malignancy life expectancy less two year , one require ongoing chemotherapeutic intervention screen Presence infection require intravenous antibiotic Pregnant nursing female . Any patient reproductive potential may participate unless he/she agree use effective contraceptive method cover informed consent process Known history HIV seropositive test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed multiple myeloma</keyword>
</DOC>